Biotechnology stocks are regaining a bit of their luster lately; but that’s done little to help boost shares in Biogen Inc. In the wake of disappointing phase 2 results for the company’s once-promising, next-generation MS drug, opicanumab, Biogen’s shares remain weak. While opicanumab’s failure is disappointing, here are three reasons why it may make sense to stick with Biogen’s shares for the long haul.
